Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817 · see citing works

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,355 · see citing works

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084 · see citing works

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Côté, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,406 · see citing works

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767 · see citing works

Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,329 · see citing works

USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2

Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199 · see citing works

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,170 · see citing works

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Press, M. F., Bernstein, L., THOMAS, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El‐Naggar, A. K., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 803 · see citing works

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

Paik, S., Hazan, R. B., Fisher, E. R., Sass, R., Fisher, B., Redmond, C. K., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594 · see citing works

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

Sauter, G., Lee, J. A., Bartlett, J. M. S., Slamon, D. J., & Press, M. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8197 · Cited by 500 · see citing works

Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience

Paik, S., Bryant, J., Tan-Chiu, E., Romond, E. H., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R. P., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.852 · Cited by 484 · see citing works

Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

Buzdar, A. U., Valero, V., Ibrahim, N. K., Francis, D., Broglio, K. R., Theriault, R. L., Pusztai, L., Green, M. C., Singletary, S. E., Hunt, K. K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1345 · Cited by 474 · see citing works

HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D. W., & Jenkins, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4744 · Cited by 437 · see citing works

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

Scaltriti, M., Verma, C. S., Guzmán, M., Jimenez, J., Parra, J.-L., Pedersen, K., Smith, D. J., Landolfi, S., y Cajal, S. R., Arribas, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 435 · see citing works

The World Health Organization Histological Typing of Breast Tumors—Second Edition

Azzopardi, J. G., Chepick, O. F., Hartmann, W., Jafarey, N. A., Llombart‐Bosch, A., Ozzello, L., Rilke, F., Sasano, N., Sobin, L. H., Sommers, S. C., et al. (1982) · American Journal of Clinical Pathology · doi:10.1093/ajcp/78.6.806 · Cited by 332 · see citing works

Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials

Press, M. F., Sauter, G., Bernstein, L., Villalobos, I. E., Mirlacher, M., Zhou, J., Wardeh, R., Li, Y.-T., Guzman, R., Ma, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0636 · Cited by 312 · see citing works

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

Liedtke, C., Broglio, K. R., Moulder, S., Hsu, L., Kau, S., Symmans, W. F., Albarracin, C. T., Meric‐Bernstam, F., Woodward, W. A., Theriault, R. L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp263 · Cited by 285 · see citing works

Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study

Burstein, H. J., Harris, L. N., Gelman, R. S., Lester, S. C., Nunes, R., Kaelin, C. M., Parker, L. M., Ellisen, L. W., Kuter, I., Gadd, M. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.124 · Cited by 280 · see citing works

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245 · see citing works

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Powell, J. E., Pegram, M. D., & Slamon, D. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8886 · Cited by 245 · see citing works

Nuclear structure in cancer tissues.

Mm, B., & Speer, F. D. (1957) · PubMed · Cited by 222 · see citing works

Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

Dybdal, N. O., Leiberman, G., Anderson, S., McCune, B. K., Bajamonde, A., Cohen, R. L., MASS, R. D., Sanders, C., & Press, M. F. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-6275-8 · Cited by 215 · see citing works

MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo

Liu, Y., El‐Ashry, D., Chen, D., Ding, I., & Kern, F. G. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00665783 · Cited by 163 · see citing works

ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

Kurokawa, H., & Arteaga, C. L. (2003) · PubMed · Cited by 139 · see citing works

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa, H., & Arteaga, C. L. (2001) · PubMed · Cited by 94 · see citing works

HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.

Pectasides, D. G., Gaglia, A., Arapantoni-Dadioti, P., Bobota, A., Valavanis, C., Kostopoulou, V., Mylonakis, N., Karabelis, A., Pectasides, M., & Economopoulos, T. (2006) · PubMed · Cited by 64 · see citing works

Trastuzumab Administration Associated with Change in HER2 Status

Dawood, S. S., Resetkova, E., & Gonzalez-Angulo, A. M. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.044 · Cited by 6 · see citing works

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,015 · see citing works

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,763 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

HER2-targeted therapies — a role beyond breast cancer

Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081 · see citing works

HER2: Biology, Detection, and Clinical Implications

Gutiérrez, C., & Schiff, R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0454-rar.1 · Cited by 657 · see citing works

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

Niikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y. Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobágyi, G. N., & Ueno, N. T. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 411 · see citing works

Targeted therapies for breast cancer

Higgins, M. J., & Baselga, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 368 · see citing works

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients

Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337 · see citing works

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

Hunter, F. W., Barker, H. R., Lipert, B. A., Rothé, F., Gebhart, G., Piccart, M. J., Sotiriou, C. P., & Jamieson, S. M. F. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0635-y · Cited by 311 · see citing works

Receptor Tyrosine Kinase-Targeted Cancer Therapy

Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297 · see citing works

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

Provenzano, E., Bossuyt, V., Viale, G., Cameron, D., Badve, S., Denkert, C., MacGrogan, G. M., Penault-Llorca, F. M., Boughey, J. C., Curigliano, G., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.74 · Cited by 296 · see citing works

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K. N., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 289 · see citing works

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Cortés, J., Fumoleau, P., Bianchi, G., Petrella, T. M., Gelmon, K. A., Pivot, X. B., Verma, S., Albanell, J., Conte, P., Lluch, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 250 · see citing works

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Bossuyt, V., Provenzano, E., Symmans, W. F., Boughey, J. C., Coles, C. E., Curigliano, G., Dixon, J. M., Esserman, L. J., Fastner, G., Kuehn, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv161 · Cited by 243 · see citing works

HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

Ithimakin, S., Day, K. C., Malik, F. A., Zen, Q., Dawsey, S. J., Bersano-Begey, T. F., Quraishi, A. A., Ignatoski, K. W., Daignault, S. D., Davis, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3349 · Cited by 234 · see citing works

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

Chandarlapaty, S., Sakr, R. A., Giri, D. D., Patil, S. N., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N. X., Hudis, C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1785 · Cited by 228 · see citing works

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke‐Hale, K., Şahin, A. A., Liu, S., Barrera, J. A., Burgués, O., Lluch, A. M., Chen, H., Hortobágyi, G. N., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1089 · Cited by 219 · see citing works

Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer

van de Ven, S., Smit, V. T. H. B. M., Dekker, T. J. A., Nortier, J. W. R., & Kroep, J. R. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.11.006 · Cited by 217 · see citing works

A Decision Support Framework for Genomically Informed Investigational Cancer Therapy

Meric‐Bernstam, F., Johnson, A. M., Holla, V. R., Bailey, A. M., Brusco, L., Chen, K., Routbort, M. J., Patel, K. P., Zeng, J., Kopetz, S., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv098 · Cited by 198 · see citing works

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis

Dieci, M. V., Barbieri, E., Piacentini, F., Ficarra, G., Bettelli, S. R., Dominici, M., Conte, P., & Guarneri, V. (2012) · Annals of Oncology · doi:10.1093/annonc/mds248 · Cited by 196 · see citing works

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 192 · see citing works

Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

Mittendorf, E. A., Jeruss, J. S., Tucker, S. L., Kolli, A. H., Newman, L. A., Gonzalez-Angulo, A. M., Buchholz, T. A., Şahin, A. A., Cormier, J. N., Buzdar, A. U., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8469 · Cited by 184 · see citing works

Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry

Niikura, N., Tomotaki, A., Miyata, H., Iwamoto, T., Kawai, M., Anan, K., Hayashi, N., Aogi, K., Ishida, T., Masuoka, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv611 · Cited by 185 · see citing works

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

Seo, S., Ryu, M., Park, Y. S., Ahn, J. Y., Park, Y., Park, S. R., Ryoo, B., Lee, G. H., Jung, H.-Y., & Kang, Y. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0891-1 · Cited by 176 · see citing works

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Esteva, F. J., Yu, D., Hung, M., & Hortobágyi, G. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.216 · Cited by 168 · see citing works

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151 · see citing works

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

Bensch, F., Brouwers, A. H., Hooge, M. N. L., de Jong, J. R., van der Vegt, B., Sleijfer, S., de Vries, E. G. E., & Schröder, C. P. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4099-8 · Cited by 149 · see citing works

Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy

Abravanel, D. L., Belka, G. K., Pan, T.-C., Pant, D. K., Collins, M. A., Sterner, C. J., & Chodosh, L. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74883 · Cited by 147 · see citing works

Neoadjuvant Therapy in the Treatment of Breast Cancer

Teshome, M. K., & Hunt, K. K. (2014) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.03.006 · Cited by 148 · see citing works

Overcoming implementation challenges of personalized cancer therapy

Meric‐Bernstam, F., & Mills, G. B. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.127 · Cited by 147 · see citing works

Treatment of HER2-overexpressing breast cancer

Baselga, J. M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq421 · Cited by 146 · see citing works

Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy

Swisher, S. K., Vila, J., Tucker, S. L., Bedrosian, I., Shaitelman, S. F., Litton, J. K., Smith, B. D., Caudle, A. S., Kuerer, H. M., & Mittendorf, E. A. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4921-5 · Cited by 137 · see citing works

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients

Guarneri, V., Dieci, M. V., Barbieri, E., Piacentini, F., Omarini, C., Ficarra, G., Bettelli, S. R., & Conte, P. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt364 · Cited by 136 · see citing works

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

Vaz-Luís, I., Ottesen, R. A., Hughes, M. E., Marcom, P. K., Moy, B., Rugo, H. S., Theriault, R. L., Wilson, J. L., Niland, J. C., Weeks, J. C., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3324 · Cited by 137 · see citing works

Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

Mendoza, M. S., González-González, M. E., Barrera, D., Dı́az, L., & Garcı́a-Becerra, R. (2015) · Europe PMC (PubMed Central) · Cited by 134 · see citing works

Targeting HER2 heterogeneity in breast cancer

Hamilton, E. P., Shastry, M., Shiller, S. M., & Ren, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102286 · Cited by 136 · see citing works

The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy

Mittendorf, E. A., Vila, J., Tucker, S. L., Chávez‐MacGregor, M., Smith, B. D., Symmans, W. F., Şahin, A. A., Hortobágyi, G. N., & Hunt, K. K. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6478 · Cited by 128 · see citing works

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

Wilking, U., Karlsson, E., Skoog, L. K., Hatschek, T., Lidbrink, E. K., Elmberger, G., Johansson, H., Lindström, L. S., & Bergh, J. C. S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1029-2 · Cited by 116 · see citing works

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Meric‐Bernstam, F., Frampton, G. M., Ferrer-Lozano, J., Yelensky, R., Fidalgo, J. A. P., Wang, Y., Palmer, G. A., Ross, J. S., Miller, V. A., Su, X., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0482 · Cited by 116 · see citing works

HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment

Sitia, L., Sevieri, M., Signati, L., Bonizzi, A., Chesi, A., Mainini, F., Corsi, F., & Mazzucchelli, S. (2022) · Cancers · doi:10.3390/cancers14102424 · Cited by 121 · see citing works

Building a Personalized Medicine Infrastructure at a Major Cancer Center

Meric‐Bernstam, F., Farhangfar, C. J., Mendelsohn, J. M., & Mills, G. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3043 · Cited by 112 · see citing works

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

Guarneri, V., Dieci, M. V., Frassoldati, A., Maiorana, A., Ficarra, G., Bettelli, S. R., Tagliafico, E., Bicciato, S., Generali, D., Cagossi, K., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0138 · Cited by 109 · see citing works

Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells

Raina, D. B., Uchida, Y., Kharbanda, A., Rajabi, H. N., Panchamoorthy, G., Jin, C., Kharbanda, S. M., Scaltriti, M., Baselga, J. M., & Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2013.308 · Cited by 108 · see citing works

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

Miglietta, F., Griguolo, G., Bottosso, M., Giarratano, T., Mele, M. L., Fassan, M., Cacciatore, M., Genovesi, E., Bartolo, D. D., Vernaci, G. M., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00434-w · Cited by 105 · see citing works

HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials

Dent, S. F., Oyan, B., Hönig, A., Mano, M. S., & Howell, S. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.01.002 · Cited by 100 · see citing works

A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines

Puig, T., Aguilar, H., Cufí, S., Oliveras, G., Turrado, C., Ortega‐Gutiérrez, S., Benhamú, B., López-Rodríguez, M. L., Urruticoechea, A., & Colomer, R. (2011) · Breast Cancer Research · doi:10.1186/bcr3077 · Cited by 98 · see citing works

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

Nahta, R., & O'Regan, R. M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2067-8 · Cited by 97 · see citing works

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Hanker, A. B., Garrett, J. T., Estrada, M. V., Moore, P. D., Ericsson, P. I. G., Koch, J. P., Langley, E. J., Singh, S., Kim, P. S., Frampton, G. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2287 · Cited by 96 · see citing works

Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway

Wilks, S. T. (2015) · The Breast · doi:10.1016/j.breast.2015.06.002 · Cited by 93 · see citing works

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer

Katayama, A., Miligy, I. M., Shiino, S., Toss, M. S., Eldib, K., Kurozumi, S., Quinn, C., Badr, N. M., Murray, C. A., Provenzano, E., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00738-5 · Cited by 88 · see citing works

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs

Dı́az-Rodrı́guez, E., Gandullo‐Sánchez, L., Ocaña, A., & Pandiella, A. (2021) · Cancers · doi:10.3390/cancers14010154 · Cited by 87 · see citing works

HER2-low expression in patients with advanced or metastatic solid tumors

Uzunparmak, B., Haymaker, C., Raso, G., Masciari, S., Wang, L., Lin, H. Y., Görür, A., Kirby, B., Cimò, A., Kennon, A. M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.005 · Cited by 83 · see citing works

Impact of obesity on breast cancer recurrence and minimal residual disease

Ecker, B. L., Lee, J. Y., Sterner, C. J., Solomon, A. C., Pant, D. K., Shen, F., Peraza, J., Vaught, L. A., Mahendra, S., Belka, G. K., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-018-1087-7 · Cited by 80 · see citing works

Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives

Criscitiello, C., André, F., Thompson, A. M., Laurentiis, M. D., Espósito, A., Gelao, L., Fumagalli, L. A. M., Locatelli, M., Minchella, I., Orsi, F., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3630 · Cited by 80 · see citing works

Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy Can Predict Patient Prognosis and Facilitate Treatment Planning

Yi, M., Buchholz, T. A., Meric‐Bernstam, F., Bedrosian, I., Hwang, R. F., Ross, M. I., Kuerer, H. M., Luo, S., Gonzalez-Angulo, A. M., Buzdar, A. U., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e318208fc2a · Cited by 77 · see citing works

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Abraham, J., Montero, A. J., Jankowitz, R. C., Salkeni, M. A., Beumer, J. H., Kiesel, B. F., Piette, F., Adamson, L. M., Nagy, R. J., Lanman, R. B., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00858 · Cited by 78 · see citing works

Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance

Chung, A. P., Cui, X., Audeh, W., & Giuliano, A. E. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.04.001 · Cited by 77 · see citing works

SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models

Li, L., Wu, Y., Wang, Z., Jia, B., Hu, Z., Dong, C., & Wang, F. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183863 · Cited by 77 · see citing works

Loss of HER2 after HER2-targeted treatment

Ignatov, T., Gorbunow, F., Eggemann, H., Ortmann, O., & Ignatov, A. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05173-4 · Cited by 74 · see citing works

Resistance to Trastuzumab

Vivekanandhan, S., & Knutson, K. L. (2022) · Cancers · doi:10.3390/cancers14205115 · Cited by 76 · see citing works

Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate

Cabaud, O., Berger, L., Crompot, E., Adélaı̈de, J., Finetti, P., Garnier, S., Guillé, A., Carbuccia, N., Farina, A. K., Agavnian, E., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0013 · Cited by 73 · see citing works

Drug-biomarker co-development in oncology – 20 years and counting

Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 72 · see citing works

Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer

Andrikopoulou, Α., Zografos, E., Liontos, M., Koutsoukos, K., Dimopoulos, M. A., & Zagouri, F. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.08.006 · Cited by 71 · see citing works

Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease

Rossi, S., Basso, M., Strippoli, A., Dadduzio, V., Cerchiaro, E., Barile, R., D’Argento, E., Cassano, A., Schinzari, G., & Barone, C. A. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.03.010 · Cited by 71 · see citing works

Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression – Implications for the practising oncologist

Gahlaut, R., Bennett, A., Fatayer, H., Dall, B. J. G., Sharma, N., Velikova, G., Perren, T. J., Dodwell, D. J., Lansdown, M., & Shaaban, A. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.006 · Cited by 70 · see citing works

Chemical technology principles for selective bioconjugation of proteins and antibodies

Chauhan, P. S., Ragendu, V., Kumar, M., Molla, R., Mishra, S. D., Basa, S., & Rai, V. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00715d · Cited by 69 · see citing works

Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?

Arnedos, M., Soria, J., André, F., & Tursz, T. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.002 · Cited by 70 · see citing works

Anti-HER2 therapy in metastatic breast cancer: many choices and future directions

Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 68 · see citing works

Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs

Blancafort, A., Giró‐Perafita, A., Oliveras, G., Palomeras, S., Turrado, C., Campuzano, Ó., Carrión-Salip, D., Massaguer, A., Brugada, R., Palafox, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131241 · Cited by 66 · see citing works

Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer

Yoshida, A., Hayashi, N., Suzuki, K., Takimoto, M., Nakamura, S., & Yamauchi, H. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24762 · Cited by 66 · see citing works

New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available

Abramson, V. G., & Arteaga, C. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1947 · Cited by 65 · see citing works

ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer

Jensen, J. D., Knoop, A. S., Ewertz, M., & Lænkholm, A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1610-3 · Cited by 65 · see citing works

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

Hassan, B., Akçakanat, A., Sangai, T., Evans, K. W., Adkins, F. C., Eterovic, A. K., Zhao, H., Chen, K., Chen, H., Do, K.-A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2337 · Cited by 61 · see citing works

Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

Kast, F., Schwill, M., Stüber, J. C., Pfundstein, S., Nagy‐Davidescu, G., Rodríguez, J. M. M., Seehusen, F., Richter, C. P., Honegger, A., Hartmann, K. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23948-6 · Cited by 60 · see citing works

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

Vicario, R., Peg, V., Morancho, B., Fluck, M. F. Z., Zhang, J., Martínez‐Barriocanal, Á., Jiménez, A. N., Aura, C. M., Burgués, O., Lluch, A. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129876 · Cited by 58 · see citing works

ERBB 3 ( HER 3) is a key sensor in the regulation of ERBB ‐mediated signaling in both low and high ERBB 2 ( HER 2) expressing cancer cells

Choi, B., Fan, X., Deng, H., Zhang, N., & An, Z. (2012) · Cancer Medicine · doi:10.1002/cam4.10 · Cited by 57 · see citing works

Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer

Miglietta, F., Dieci, M. V., Griguolo, G., & Guarneri, V. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102222 · Cited by 57 · see citing works

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression

Kalinsky, K. M., Heguy, A., Bhanot, U. K., Patil, S. N., & Moynahan, M. E. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1601-4 · Cited by 57 · see citing works

Biomarkers of residual disease after neoadjuvant therapy for breast cancer

Penault-Llorca, F. M., & Radosevic‐Robin, N. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.1 · Cited by 57 · see citing works

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

Nadal‐Serrano, M., Morancho, B., Escrivá-de-Romaní, S., Morales, C. B., Luque-García, A., Escorihuela, M., Espinosa-Bravo, M., Peg, V., Dijcks, F. A., Dokter, W. H. A., et al. (2020) · Cancers · doi:10.3390/cancers12030670 · Cited by 57 · see citing works

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

Azuma, K., Tsurutani, J., Sakai, K., Kaneda, H., Fujisaka, Y., Takeda, M., Watatani, M., Arao, T., Satoh, T., Okamoto, I., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.002 · Cited by 55 · see citing works

Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence After Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy

Akay, C. L., Meric‐Bernstam, F., Hunt, K. K., Grubbs, E. G., Bedrosian, I., Tucker, S. L., Kuerer, H. M., Hoffman, K. E., Babiera, G. V., Strom, E. A., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2006-7 · Cited by 55 · see citing works

Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

Scaltriti, M., Serra, V., Normant, E., Guzmán, M., Rodríguez, O., Lim, A. R., Slocum, K. L., West, K. A., Rodriguez, V., Prudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0966 · Cited by 54 · see citing works

Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study

Beltrame, L., Marino, M. D., Fruscio, R., Calura, E., Chapman, B., Clivio, L., Sina, F. P., Mele, C., Iatropoulos, P., Grassi, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv164 · Cited by 54 · see citing works

Targeting ERBB2 ( HER2 ) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications

Dumbrava, E. E. I., Balaji, K., Raghav, K. P. S., Hess, K. R., Javle, M. M., Blum-Murphy, M. A., Ajani, J. A., Kopetz, S., Broaddus, R. R., Routbort, M. J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00345 · Cited by 56 · see citing works

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance

Zhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 54 · see citing works

Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy

Montagna, E., Bagnardi, V., Viale, G., Rotmensz, N., Sporchia, A., Cancello, G., Balduzzi, A., Galimberti, V. E., Veronesi, P., Luini, A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu528 · Cited by 53 · see citing works

Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant

Robertson, S., Rönnlund, C., de Boniface, J., & Hartman, J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05119-2 · Cited by 53 · see citing works

The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?

Arnedos, M., Vielh, P. R., Soria, J., & André, F. (2013) · The Journal of Pathology · doi:10.1002/path.4276 · Cited by 51 · see citing works

Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment

Xiao, C., Gong, Y. Y., Han, E., Gonzalez-Angulo, A. M., & Sneige, N. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq623 · Cited by 51 · see citing works

Cellular dormancy in minimal residual disease following targeted therapy

Ruth, J. R., Pant, D. K., Pan, T.-C., Seidel, H. E., Baksh, S. C., Keister, B. A., Singh, R., Sterner, C. J., Bakewell, S. J., Moody, S. E., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01416-9 · Cited by 51 · see citing works

Antibody–Drug Conjugates for Tumor Targeting—Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins

Merten, H., Brandl, F., Plückthun, A., & Zangemeister‐Wittke, U. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00260 · Cited by 48 · see citing works

Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis

Wang, R.-X., Chen, S., Jin, X., Chen, C.-M., & Shao, Z. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4064-9 · Cited by 48 · see citing works

Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes

Parinyanitikul, N., Lei, X. J., Chávez‐MacGregor, M., Liu, S., Mittendorf, E. A., Litton, J. K., Woodward, W. A., Zhang, A. (., Hortobágyi, G. N., Valero, V., et al. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.09.006 · Cited by 47 · see citing works

Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues

Kennedy, J. J., Whiteaker, J. R., Kennedy, L. C., Bosch, D. E., Lerch, M. L., Schoenherr, R. M., Zhao, L., Lin, C., Chowdhury, S., Kilgore, M., et al. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab047 · Cited by 46 · see citing works

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

O’Shaughnessy, J., Brufsky, A., Rugo, H. S., Tolaney, S. M., Punie, K., Sardesai, S. D., Hamilton, E. P., Loirat, D., Traina, T. A., Leon-Ferre, R. A., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06602-7 · Cited by 47 · see citing works

Effect of HER2 status on distant recurrence in early stage breast cancer

Hess, K. R., & Esteva, F. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2366-0 · Cited by 45 · see citing works

Quantification of HER family receptors in breast cancer

Nuciforo, P. G., Radosevic‐Robin, N., Ng, T., & Scaltriti, M. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0561-8 · Cited by 45 · see citing works

Applying the New Guidelines of HER2 Testing in Breast Cancer

Zhang, H., Moisini, I., Ajabnoor, R. M., Turner, B. M., & Hicks, D. G. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0901-4 · Cited by 45 · see citing works

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Loibl, S., Huang, C., Mano, M. S., Mamounas, E. P., Geyer, C. E., Untch, M., Théry, J., Schwaner, I., Limentani, S. A., Loman, N., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00477-z · Cited by 44 · see citing works

Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes

Wetzel, C. L., Sutton, T. L., Gardiner, S. K., Farinola, M. A., Johnson, N., & Garreau, J. R. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26646 · Cited by 15 · see citing works

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

Guiu, S., Gauthier, M., Coudert, B. P., Bonnetain, F., Favier, L., Ladoire, S., Tixier, H., Guiu, B., Penault-Llorca, F. M., Ettore, F., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605939 · Cited by 48 · see citing works

Pathologic Complete Response and Survival after Trastuzumab-Based Neoadjuvant Therapy According to the Level of HER2-Amplification.

Guiu, S., Liegard, M., Tixier, H., Guy, F., Fumoleau, P., Coudert, B. P., & Arnould, L. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-1089

Relationship between levels of HER-2 amplification and pathologic complete response to trastuzumab-based neoadjuvant treatment.

Masini, C., Bisagni, A., Falco, G., Bassano, C., Baldi, L., Bisagni, G., Moretti, G., Albini, A., Ferrari, G., Boni, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e11605

Treatment of HER2+ breast cancer: a retrospective of disease prognosis with loss of HER2 amplification on residual disease after neoadjuvant treatment in a community hospital setting.

Uczkowski, D., Sekhri, A., Gupta, S., Gendler, L. S., Misiukiewicz, K. J., Levin, M. B., & Guerin, B. (2023) · PubMed Central · Cited by 4 · see citing works